



	Questions : Lok Sabha




























Screen Reader Access
Skip to Main Content
Skip to Navigation



Text Size

                                A

                                A
A















हिन्दी मे








Parliament of India Lok Sabha House of the
                        People






* Special Characters not allowed












India Time 


Your Time 


                        Monday,
                        11 April 2022









HomeMembersSitting MembersMembers Home PageMembers' PortalContact DetailsMembers SearchStatistical AnalysisAttendance of MembersHandbook Members Since 1952Digitized Who's WhoOthers BusinessProvisional CalendarList of BusinessPapers to be LaidList of Private Members' BusinessBulletin-IDigitized Lok Sabha Bulletin Part IBulletin-IIStatement of WorkSpecial Mentions (ZERO HOUR)Resume of WorkDigitized Resume of Work done by Lok Sabha QuestionsHomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions DebatesIntroductionSynopsisUncorrected DebateText of DebateDigitized DebatesConstituent Assembly DebatesWit And HumourDebate SearchHindi FontsDisclaimer Papers LaidPapers Laid on the Table of the House LegislationIntroduction(How Bill Becomes Act)Bills IntroducedBills PassedBills PendingBills AssentedBills LapsedBills WithdrawnBills NegativedBills Search Disclaimer CommitteesIntroductionChairpersonSummary of WorkCommittee Meetings ScheduleBills Referred to CommitteesReports PresentedDigitized ReportsPress ReleaseMembership SearchToday's Committee MeetingsCommittee Subject SelectedDepartment Related-RS Govt. AssurancesSANSAD TVIntranet





HomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions











Download as PDF




Print












PDF/WORD(Hindi)


PDF/WORD




                                    GOVERNMENT OF INDIA
                                





                                    MINISTRY OF
                                    HEALTH AND FAMILY WELFARE






                                    LOK SABHA
                                





UNSTARRED 


                                    QUESTION NO:
                                

4053






                                    ANSWERED ON: 
                                

19.03.2021






COVID Vaccines Developed by Foreign Countries




Dayanidhi Maran














                        Will the Minister of





HEALTH AND FAMILY WELFARE


                        be pleased to state:-















                                                    Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:(a) whether the Government proposes to allow the usage, sale and distribution of foreign orgin COVID vaccines developed by foreign countries;(b) the regulatory requirements being imposed on foreign manufacturers for approval of their medicines;(c) whether the indigenous/local vaccines are also required to furnish the same requirements for regulatory approvals;(d) if so, the details thereof; and(e) whether the Government has conducted any consultations, discussions, review of vaccines such as Pfizer, Moderna etc., if so, the details thereof?






ANSWER




                                                        ANSWERTHE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE(SHRI ASHWINI KUMAR CHOUBEY)(a): The Central Drugs Standard Control Organization (CDSCO) had received applications regarding grant of import permission to import (marketing authorization) the following vaccines developed by foreign countries:i) M/s Dr. Reddy’s Laboratories Ltd., Hyderabad for grant of import permission to import (marketing authorization) from Russia for emergency use of COVID-19 Vaccine in the country on 19.02.2021. The proposal was deliberated in the Subject Expert Committee (COVID) meeting of CDSCO held on 24.02.2021 and as per the recommendation of the committee, the firm has been requested to submit immunogenicity and safety data of Phase II and III trial as per approved protocol for further consideration of the Committee.ii) M/s Pfizer Limited, Mumbai for grant of permission to import (marketing authorization) for emergency use of its COVID-19 vaccine in the country on 04.12.2020. However, the application was withdrawn by the firm on 05.02.2021.(b) to (d): The detailed guidelines and requirements for approval to conduct of clinical trial and marketing authorization permission of New Drugs including vaccines are specified in Second Schedule of the New Drugs and Clinical Trial (ND & CT) Rules, 2019. The approval of new drug or vaccine for manufacturing and marketing is based on the submission of adequate data including Chemistry, Manufacturing and Control (CMC), non-clinical (animal studies), clinical trial data as per Rules and outcomes of evaluation of the same in consultation with Subject Expert Committee (SEC) of CDSCO.In the case of import from other countries, before approval of such new drug or vaccine in India, local clinical trial may be required to be carried out as per the provisions of New Drugs and Clinical Trials Rules, 2019 to generate evidence of efficacy and safety of the vaccine in Indian population.(e): CDSCO received an application from M/s Pfizer for grant of permission to import its COVID-19 vaccine in the country on 04.12.2020. The proposal was deliberated in the SEC (COVID) meeting held on 03.02.2021. The committee noted that incidents of palsy, anaphylaxis and other SAE’s were reported during post marketing and the causality of the events with the vaccine was under investigation. Also, the firm had not proposed any plan to generate safety and immunogenicity data in Indian population. After detailed deliberation, the committee did not recommend for grant of permission for emergency use in the country at that stage. However, the firm on 05.02021 withdrew its application.CDSCO has not received any application for approval of COVID-19 Vaccine of M/s Moderna.
























HomeArchiveIndex to Select Questions (1984-1999)Ballot ListStatistical Statements Relating to QuestionsUploading of Questions - Status QueryProcedure for Sending Text of Questions & AnswersDemarcation of responsibilities in Govt. of IndiaBrochure on Statutory Corporations, Companies and Other Bodies in Which the Government of India have financial or controlling interestHighlights pertaining to questions of 17th Lok Sabha






Contact Us 
Disclaimer











        Developed and Hosted by National Informatics Centre (NIC)

Content on this website is published,
            managed & maintained by Software Unit, Computer (HW & SW) Management. Branch,
            Lok Sabha Secretariat





HomeMembersBusinessQuestionsDebatesPapers Laid


LegislationCommitteesSANSAD TVIntranetSecretariatPRIDE


RecruitmentSC/ST ReservationConferenceParliament Library


About ParliamentPhoto GalleryRelated LinksRTITendersFAQ


SpeakerDy. SpeakerLeader of the HousePanel of ChairpersonsContact UsFeedback


Council of MinistersPublications of MinistriesParliamentry ProceduresJournal of Parliamentary Information
Visitor's Counter:113210370







Copyright
Privacy Policy
Disclaimer
Terms &
                Conditions

                Accessibility Statement
Accessibility
                Options
Feedback
Site Map







